Integril Injection 2 mg/ml contains Eptifibatide, a potent antiplatelet agent used in the management of acute coronary syndromes (ACS) and during percutaneous coronary intervention (PCI). Eptifibatide belongs to the class of glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitors and works by preventing platelet aggregation, thereby reducing the risk of thrombus formation in patients with ischemic heart disease.

Integril Injection is administered intravenously in hospital settings under close medical supervision and is commonly used in combination with aspirin and heparin to improve clinical outcomes in high-risk cardiac patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Antiplatelet Agents

• Glycoprotein IIb/IIIa Inhibitors

Composition

Each milliliter of injection contains:

• Eptifibatide 2 mg

Indications

Integril Injection 2 mg/ml is indicated for the prevention of early myocardial infarction in patients with acute coronary syndromes, including:

• Unstable angina

• Non-ST-segment elevation myocardial infarction (NSTEMI)

• Patients undergoing percutaneous coronary intervention (PCI), including angioplasty and stent placement

It is used as an adjunct to standard therapy with aspirin and unfractionated heparin.

Pharmacology

Eptifibatide is a cyclic heptapeptide that selectively and reversibly inhibits the platelet glycoprotein IIb/IIIa receptor. This receptor plays a central role in platelet aggregation by binding fibrinogen and von Willebrand factor, leading to cross-linking of platelets and thrombus formation.

By blocking GP IIb/IIIa receptors, Eptifibatide prevents the final common pathway of platelet aggregation, thereby reducing the formation of intracoronary thrombi. Its rapid onset and short duration of action allow for effective antiplatelet control during acute cardiac events while enabling relatively quick recovery of platelet function after discontinuation.

Dosage and Administration

Integril Injection is administered intravenously and must be used under specialist supervision.

Adults:

• Acute coronary syndrome: Initial intravenous bolus followed by continuous infusion as per standard treatment protocol

• During PCI: A bolus dose is given immediately before the procedure, followed by continuous infusion for a specified duration

Dosage adjustment may be required in patients with renal impairment. Continuous monitoring for bleeding and platelet count is recommended during therapy.

Contraindications

Integril Injection 2 mg/ml is contraindicated in patients with:

• Active internal bleeding or recent history of bleeding disorders

• History of hemorrhagic stroke or intracranial hemorrhage

• Severe uncontrolled hypertension

• Thrombocytopenia

• Hypersensitivity to Eptifibatide or any component of the formulation

Drug Interactions

• Increased risk of bleeding when used with other antiplatelet agents, anticoagulants, or thrombolytics

• Caution is advised when used with NSAIDs and other drugs affecting hemostasis

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

The most commonly reported adverse effect is bleeding, which may include:

• Minor bleeding at injection or catheter sites

• Gastrointestinal bleeding

• Rare cases of serious hemorrhage

Other possible side effects include hypotension, nausea, and thrombocytopenia.

Pregnancy and Lactation

The safety of Eptifibatide during pregnancy and lactation has not been well established. Integril Injection should be used only if clearly necessary and when the potential benefit outweighs the potential risk, as determined by a physician.

Precautions and Warnings

• Use with caution in patients at increased risk of bleeding

• Platelet counts should be monitored before and during treatment

• Discontinue immediately if severe bleeding or thrombocytopenia occurs

Storage Conditions

Store below 25°C in a cool and dry place.
Protect from light.
Keep out of reach of children.